Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative

"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."
Michael DeMarco, PhD

by Michael DeMarco, PhD

Spotlight: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative
"The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling adoption in hospital, outpatient, and home-care settings."
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx™), Aligned with FDA’s CNPV National Priority Initiative
TORONTO, August 27, 2025-- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of…
PharmaTher Holdings Ltd. Ketamine
Ketamine Ketarx
The ketamine patch has been in development for several years and is designed to deliver controlled, sustained analgesia for both acute postoperative pain and chronic pain conditions, enabling…
PharmaTher Holdings Ltd. Ketamine

More like this

Is ketamine a "psychedelic"?

Yes.

Spotlight: A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Mus musculus) (Rocha, et al, 2025)

"No significant alterations were observed in liver and kidney function in either sex, nor in inflammation, apoptosis, or DNA damage in kidney tissues. Overall, these findings support the viability of voluntary oral ketamine administration and accentuate the need to refine the proposed model"

Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)

"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."

Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)

"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."

Spotlight: Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression (Manza, et al, 2025)

Ketamine was safe and generally well-tolerated. At 10-day follow-up post-ketamine infusions, participant acceptability ratings were mostly favorable. 3-month timepoint - strong treatment adherence with self-reported depression symptoms decrease

Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)

"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "
Mastodon Mastodon